FDA and AACR to host DPYD testing workshop in January 2025

The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence and the American Association for Cancer Research (AACR) are hosting a one day workshop to discuss DPYD testing.

The purpose of this workshop is to provide an interdisciplinary forum to examine the existing information and evidence surrounding DPD deficiency testing, consider the potential clinical implications of requiring testing, including potential unintended consequences, and to discuss the regulatory considerations for modifying FDA product labeling to require testing. (quoted from AACR website)

Pharmacogenomics community members can register to participate in person (Bethesda) or virtually for this meeting on January 16, 2025 via links to sign up at AACR.

Meeting Goals

• To discuss the current DPD deficiency testing landscape, including history, and testing over the years
• To understand current clinical approaches to DPD deficiency testing of oncology healthcare practitioners
• To examine potential approaches for advancing the field and moving forward
  (quoted from FDA website)